Table of Contents
- Definition and Epidemiology of MPGN
- Etiology of Membranoproliferative Glomerulonephritis
- Pathology and Pathophysiology of MPGN
- Symptoms of Membranoproliferative Glomerulonephritis
- Diagnosis of Membranoproliferative Glomerulonephritis
- Therapy of Membranoproliferative Glomerulonephritis
- Progression and Prognosis of MPGN
Definition and Epidemiology of MPGN
Membranoproliferative glomerulonephritis (MPGN) is a pattern of glomerular injury that is caused by an immune mediated reaction. The disease process involves thickening of the glomerular basement membranes, and proliferative changes, including hypercellularity of the glomerulus and increased mesangial matrix. Other names for MPGN include mesangiocapillary glomerulonephritis and lobar glomerulonephritis.
MPGN is classified into three groups of disorders: type I MPGN, type II MPGN and type III MPGN.
- Type I MPGN involves the deposition of immune complexes made up of IgG and complement.
- Type II MPGN is also called dense deposit disease, and complement activation is a key part of this disorder. Type II MPGN falls under a group of disorders known as C3 glomerulopathies.
- Little is known about type III MPGN, which is relatively rarer, so only types I and II MPGN will be the focus of this article.
MPGN is a rare glomerular disease, and seems to be decreasing in prevalence. Most patients who present with primary MPGN are adolescents or young adults – over 75% of cases are diagnosed in patients aged 8 to 16. Also, 10% of cases of nephrotic syndrome that occur in children and young adults are caused by MPGN.
Etiology of Membranoproliferative Glomerulonephritis
MPGN may be referred to as primary MPGN or secondary MPGN, depending on the cause. If the etiology is unknown, then it is called primary or idiopathic MPGN. However, it is thought that antigens in primary MPGN originate from infectious particles such as viruses (e.g. hepatitis B and C). These antigens may become lodged within the glomerulus or form immune complexes first and then deposit within the glomerulus.
In cases where there is a known etiologic agent or an association with a systemic disorder, it is called secondary MPGN. Cases of secondary MPGN are becoming more common as the cause is being increasingly identified. Disorders associated with secondary MPGN include immune complex disorders such as systemic lupus erythematosus and Henoch-Schönlein Purpura, systemic infections such as hepatitis B, hepatitis C, endocarditis, chronic abscesses, Human Immunodeficiency Virus and schistosomiasis, malignancies such as chronic lymphocytic leukaemia, and α1-antitrypsin deficiency.
Cases of type II MPGN are generally idiopathic whereas type 1 MPGN are usually secondary MPGN with an apparent underlying cause.
Pathology and Pathophysiology of MPGN
Membranoproliferative glomerulonephritis at cellular level
The name of MPGN offers a clue about its histopathology. Primary features include thickening of the glomerular basement membrane (“membrano”) and glomerular cell proliferation or hypercellularity (“proliferative”). Glomerular cell proliferation includes cells of the mesangium and capillary endothelium, as well as an infiltration of leukocytes, including neutrophils and mononuclear cells.
Deposits are present in the capillary walls and mesangial regions of the glomerulus. Crescent cells may also be present within Bowman’s spaces. Numerous crescent cells appear when MPGN evolves into rapidly progressive glomerulonephritis.
The thickened glomerular capillary basement membrane resembles a “tram-track” appearance on light microscopy with certain stains such as the Periodic Acid Schiff stain. There is also a “splitting” or duplication of the basement membrane with cellular components present in between the duplicated membrane.
While type I MPGN and type II MPGN share a similar morphology, there is a difference in the composition of these deposits. In type I MPGN, the deposits are composed of immune complexes. Immune complexes are formed when there is an inappropriate production of antibodies in response to a nephritogenic antigen. Circulating immune complexes then deposit in the glomerulus, resulting in complement activation and this triggers a cascade of inflammatory events. Type 1 MPGN involves activation of classical and alternative complement pathways.
It should be noted that the deposits in type I MPGN are primarily subendothelial deposits, but there may be mesangial and subepithelial deposits too.
In type II MPGN, the deposits are composed of an unknown material. In contrast to type I, type II MPGN mostly features ribbons of dense intramembranous deposits. In type II MPGN, complement activation also plays a key role, but complement is present only in the glomerular basement membrane and not in the deposits.
Symptoms of Membranoproliferative Glomerulonephritis
MPGN can present with the following signs and symptoms:
Patients may present with nephrotic syndrome, nephritic syndrome, or asymptomatic proteinuria and hematuria.
The majority of patients (about 50%) present with signs and symptoms of nephrotic syndrome, which is characterized by massive proteinuria (>3.5g/24 hours), hypoalbuminemia, edema and hyperlipidemia.
Asymptomatic proteinuria (that is not in the nephrotic range) and hematuria is the primary presentation in 25% of cases. In another 25% of cases, patients present with acute nephritic syndrome.
The variability of the clinical presentation of MPGN mirrors the disease process. During the initial acute injury and proliferative phase, patients may present with a nephritic picture. Later with disease progression and reparative changes, patients present with nephrotic syndrome. The presentation may also be influenced by the type of MPGN.
Diagnosis of Membranoproliferative Glomerulonephritis
Clinical and lab findings are non-specific as there are a wide range of causes of nephrotic or nephritic syndrome. MPGN is confirmed with a histological diagnosis using a renal biopsy specimen.
Urinalysis reveals proteinuria and hematuria. Urine microscopy will often show dysmorphic red blood cells (acanthocytes), leukocytes and RBC casts, indicative of glomerulonephritis. 24-hour urinary protein can be measured to quantify the proteinuria, or a spot urine protein-to-creatinine ratio. Nephrotic range proteinuria (>3g/24h) is present in about 50% of cases.
Blood tests are also helpful. Some patients will have elevated creatinine and blood urea nitrogen (BUN) levels. A degree of azotemia is present in 50% of cases, but it is the patients presenting with nephritic syndrome who often have significantly reduced GFR. Complement levels should also be ascertained, since hypocomplementemia can occur in all types of MPGN. C3 and C4 levels are both reduced in type I MPGN. In type II MPGN, C3 levels are more reduced than C4, as the alternative complement pathway is preferentially activated.
Lab tests should also be done to look for possible secondary causes of MPGN. This includes tests such as viral serology for hepatitis B and C, an autoimmune screen for rheumatological disorders such as SLE, blood cultures for endocarditis, tests for monoclonal gammopathies, including croglobulins.
A renal ultrasound is usually done prior to a biopsy, looking for evidence of chronic kidney disease.
Imaging tests may also be done if a certain secondary cause of MPGN is suspected such as a chronic abscess, in which case CT imaging may be useful, or endocarditis, using a echocardiogram for diagnostic confirmation.
A renal biopsy enables a definitive diagnosis of MPGN. Light microscopy shows glomerular basement membrane thickening and glomerular hypercellularity. Immunofluorescence studies show diffuse intense granular staining of the mesangium and capillary loops with C3, IgG and IgM.
On electron microscopy, subendothelial deposits and mesangial deposits are pathognomonic of MPGN (type I). In type II MPGN, dense intramembranous deposits are pathognomonic of this disease process.
Differential diagnosis of membranoproliferative glomerulonephritis
There are many different types of glomerular disease, either primary or secondary, that can result in a similar presentation of nephrotic or nephritic syndrome in patients, including:
- Acute glomerulonephritis e.g. poststreptococcal glomerulonephritis (often preceded by a streptococcal throat infection; streptococcal antibody titers are positive)
- Lupus nephritis (one of the manifestations of the multisystem immune disorder, lupus (SLE). The patient may have other features, best remembered with the SOAPBRAINMD mnemonic: serositis, oral ulcers, arthritis, photosensitivity, blood dyscrasias, renal involvement, ANA positive, immunologic phenomena [anti-dsDNA, antiphospholipid antibodies), malar rash, discoid rash)
- Minimal change disease (most common cause of nephrotic syndrome in children; “minimal change” with podocyte effacement seen on electron microscopy of the renal biopsy)
- Focal segmental glomerulosclerosis (renal biopsy demonstrates focal and segment sclerosis of the glomeruli)
- Membranous nephropathy
- Diabetic nephropathy (patient has a long-standing history of diabetes)
- IgA nephropathy (episodic hematuria accompanied by pharyngitis)
- Rapidly progressive glomerulonephritis (numerous crescent cells on renal biopsy)
Therapy of Membranoproliferative Glomerulonephritis
The treatment of type 1 MPGN or cases of secondary MPGN is with treatment of the underlying cause, such as treatment of associated infection (e.g. hepatitis C), autoimmune disorder (e.g. SLE) or neoplasm.
For type II MPGN, however, there is no established treatment at present. In some cases, immunosuppressive therapy with steroids may be trialled. Other drugs such as anti-platelets (e.g. aspirin, dipyridamole), anticoagulants (e.g. warfarin) and cytotoxic agents (e.g. cyclophosphamide) have no demonstrated benefit in MPGN.
Progression and Prognosis of MPGN
The rule of thirds is a useful way to remember the prognosis of MPGN. About one third of patients undergo spontaneous remission. One third experience persistent symptoms with a variable course, and one third experience progressive decline and develop end stage kidney disease.
Prognosis of MPGN depends on a patient’s presentation and clinical features. Those who present with mild proteinuria and asymptomatic hematuria tend to follow a relatively benign course. More severe presentations, with heavier proteinuria, nephrotic syndrome, hypertension, advanced azotemia, nephritic syndrome, or the presence of crescents on renal biopsy, follow a more rapidly deteriorating course. This is often referred to as rapidly progressive glomerulonephritis.
In 35-60% of patients, chronic renal failure occurs after 10 years following diagnosis. However, after 20 years, about 90% of patients develop renal failure.
The prognosis for type II MPGN is poorer than that of type I MPGN. An important contributing factor is the lack of established treatment for type II MPGN (generally primary or idiopathic MPGN).